Abstract
The effects of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] on gene expression and function were studied in Caco-2 cells. Microarray analyses, real-time quantitative polymerase chain reactions, and Western blotting were used to determine the mRNA and protein expression of transporters and enzymes after 1,25(OH)2D3 or vehicle (0.1% ethanol) treatment for 1, 3, 6, and 10 days. The mRNA and protein expressions of the apical sodium-dependent bile acid transporter, oligopeptide transporter 1, multidrug resistance-associated protein (MRP) 3, and sulfotransferase 1E1 remained unchanged with 1,25(OH)2D3 treatment, whereas those for CYP3A4, multidrug resistance protein 1, and MRP2 were significantly increased (P < 0.05). 1,25(OH)2D3 treatment significantly enhanced MRP4 protein expression by increasing protein stability without affecting mRNA expression, as confirmed in cycloheximide experiments. Marked increase in 6β-hydroxylation of testosterone by CYP3A4 was also observed in the 6-day 1,25(OH)2D3-treated (100 nM) cell lysate. The transport of [3H]digoxin, the P-glycoprotein (P-gp) substrate, after treatment with 100 nM 1,25(OH)2D3 for 3 days revealed a higher apparent permeability (Papp) value in the basal (B)-to-apical (A) direction over that of vehicle treatment (15.1 ± 0.53 × 10-6 versus 11.8 ± 0.58 × 10-6 cm/s; P < 0.05), whereas the Papp in the A-to-B direction was unchanged; the efflux ratio was increased (from 5.8 to 8.0). Reduced cellular retention of 5-(and-6)-carboxy-2′,7′-dichlorofluorescein, suggestive of higher MRP2 activity, was observed in the 3-day 100 nM 1,25(OH)2D3-treated cells over controls. Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1α-hydroxyvitamin D3,1α-hydroxyvitamin D2 or Hectorol, and 25-hydroxyvitamin D3) in Caco-2 cells, suggesting a role of 1,25(OH)2D3 and analogs in the activation of enzymes and transporters via the vitamin D receptor.
Footnotes
-
This study was supported by the Canadian Institutes for Health Research [Grant MOP89850].
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.149815.
-
ABBREVIATIONS: P-gp, P-glycoprotein; MDR1, multidrug resistance protein 1; MRP, multidrug resistance-associated protein; PXR, pregnane X receptor; CAR, constitutive androstane receptor; VDR, vitamin D receptor; VDRE, vitamin D response element; SULT, sulfotransferase; ASBT, apical sodium dependent bile acid transporter; PEPT1, oligopeptide transporter 1; 1,25(OH)2D3,1α,25-dihydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3;lα(OH)D3,1α-hydroxyvitamin D3;lα(OH)D2,1α-hydroxyvitamin D2 or Hectorol; CDF, 5-(and-6)-carboxy-2′,7′-dichlorofluorescein; CDF-DA, 5-(and-6)-carboxy-2′,7′-dichlorofluorescein diacetate; DMEM, Dulbecco's modified Eagle's medium; HPLC, high-performance liquid chromatography; RT-qPCR, real-time quantitative polymerase chain reaction; aRNA, aberrant RNA; FBS, fetal bovine serum; EfR, efflux ratio; ITS, insulin-transferrin-selenium; SSC, standard saline citrate; TEER, transepithelial electrical resistance; A, apical; B, basolateral; HBSS, Hanks' balanced salt solution; Papp, apparent permeability; PBS, phosphate-buffered saline; DBP, vitamin D binding protein; PMEA, 9-(2-phosphonylmethoxyethyl)adenine; POM, pivaloxymethyl.
- Received December 15, 2008.
- Accepted May 1, 2009.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|